Entry of oxime K027 into the different parts of rat brain: Comparison with obidoxime and oxime HI-6

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10190527" target="_blank" >RIV/00179906:_____/14:10190527 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/14:43875081

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1214021X13000069#" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1214021X13000069#</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jab.2013.01.001" target="_blank" >10.1016/j.jab.2013.01.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Entry of oxime K027 into the different parts of rat brain: Comparison with obidoxime and oxime HI-6

Popis výsledku v původním jazyce

Acetylcholinesterase reactivators (oximes) are highly hydrophilic compounds. This factor is considered to limit their distribution through the human body, especially into the central nervous system. However, some results contradict this hypothesis and confirm low concentrations of oximes inside the CNS. This study aims to verify oxime penetration through the blood-brain barrier, and into different brain regions. It has been confirmed that oximes can penetrate the BBB after therapeutic dose administration (0.73%, 0.69%, and 0.52% corresponding to obidoxime, HI-6, and new oxime K027). Although the whole brain level of K027 seems to be lower compared with other oximes we have to keep in mind that these numbers represent only a percentage of the concentration found in plasma. So, for more adequate comparison it is essential to have a look at the actual concentration of oximes in the wet brain tissue: 106.6 19.87 ng/g (K027), 49.88 10.21 ng/g (obidoxime) and 86.51 42.37 ng/g (HI-6), where c

Název v anglickém jazyce

Entry of oxime K027 into the different parts of rat brain: Comparison with obidoxime and oxime HI-6

Popis výsledku anglicky

Acetylcholinesterase reactivators (oximes) are highly hydrophilic compounds. This factor is considered to limit their distribution through the human body, especially into the central nervous system. However, some results contradict this hypothesis and confirm low concentrations of oximes inside the CNS. This study aims to verify oxime penetration through the blood-brain barrier, and into different brain regions. It has been confirmed that oximes can penetrate the BBB after therapeutic dose administration (0.73%, 0.69%, and 0.52% corresponding to obidoxime, HI-6, and new oxime K027). Although the whole brain level of K027 seems to be lower compared with other oximes we have to keep in mind that these numbers represent only a percentage of the concentration found in plasma. So, for more adequate comparison it is essential to have a look at the actual concentration of oximes in the wet brain tissue: 106.6 19.87 ng/g (K027), 49.88 10.21 ng/g (obidoxime) and 86.51 42.37 ng/g (HI-6), where c

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12062" target="_blank" >NT12062: Příprava a hodnocení účinnosti nových terapeutik proti otravám pesticidy</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Applied Biomedicine

ISSN

1214-021X

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

25-29

Kód UT WoS článku

000333504400003

EID výsledku v databázi Scopus

—